1887
Rapid communication Open Access
Like 0

Abstract

During 2023/24, all children aged 6 to 59 months were targeted for seasonal influenza vaccination in Spain nationally. Using a test-negative case–control design with sentinel surveillance data, we estimated adjusted influenza vaccine effectiveness (IVE) against any influenza type to be 70% (95% confidence interval (CI): 51 to 81%) for primary care patients with acute respiratory illness (ARI) and 77% (95% CI: 21 to 93%) for hospitalised patients with severe ARI. In primary care, where most subtyped viruses (61%; 145/237) were A(H1N1), adjusted IVE was 77% (95% CI: 56 to 88%) against A(H1N1)pdm09.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.40.2400618
2024-10-03
2024-12-21
/content/10.2807/1560-7917.ES.2024.29.40.2400618
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/40/eurosurv-29-40-1.html?itemId=/content/10.2807/1560-7917.ES.2024.29.40.2400618&mimeType=html&fmt=ahah

References

  1. Wang X, Li Y, O’Brien KL, Madhi SA, Widdowson MA, Byass P, et al. , Respiratory Virus Global Epidemiology Network. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health. 2020;8(4):e497-510.  https://doi.org/10.1016/S2214-109X(19)30545-5  PMID: 32087815 
  2. Grupo de trabajo de Recomendaciones de Vacunación frente a gripe en población infantil de 6 a 59 meses de la Ponencia de Programa y Registro de Vacunaciones. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. [Working Group on Vaccination Recommendations for Influenza in Children Aged 6 to 59 Months from the Vaccination Program and Registry Committee]. Madrid: Ministerio de Sanidad, Oct 2022. Spanish. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/programasDeVacunacion/docs/Recomendaciones_vacunacion_gripe_PoblacionInfantil.pdf
  3. Nayak J, Hoy G, Gordon A. Influenza in Children. Cold Spring Harb Perspect Med. 2021;11(1):a038430.  https://doi.org/10.1101/cshperspect.a038430  PMID: 31871228 
  4. Ponencia de Programa y Registro de Vacunaciones. Recomendaciones de vacunación frente a gripe y COVID-19 en la temporada 2023-2024 en España. Actualización. [Recommendations against influenza and COVID-19 in the 2023/24 season in Spain; update]. 2023 sep. Spanish. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/programasDeVacunacion/docs/Recomendaciones_vacunacion_gripe.pdf
  5. Ministerio de Sanidad. Sistema de Información de Vacunaciones del Ministerio de Sanidad (SIVAMIN), Aplicación interactiva. [Ministry of Health. Vaccination Information System of the Ministry of Health (SIVAMIN), Interactive Application]. Spanish. [Accessed 01 Oct 2024]. Available from: https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/I/sivamin/sivamin
  6. Red Nacional de Vigilancia Epidemiológica (RENAVE), Centro Nacional de Epidemiología, Centro Nacional de Microbiología. Instituto de Salud Carlos III. Protocolo para la vigilancia centinela de Infección respiratoria aguda (IRAs) en Atención Primaria en España Temporada 2023-24. [Protocol for Sentinel Surveillance of Acute Respiratory Infections (ARI) in Primary Care in Spain for the 2023-24 Season]. 2023. Spanish. Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/GRIPE/Protocolos/Protocolo%20Vigilancia%20centinela%20de%20IRAs_2023-24_v.27092023.pdf
  7. Red Nacional de Vigilancia Epidemiológica (RENAVE), Centro Nacional de Epidemiología, Centro Nacional de Microbiología. Instituto de Salud Carlos III. Protocolo para la vigilancia centinela de infección respiratoria aguda grave (IRAG) en hospitales en España Temporada 2023-24. [Protocol for Sentinel Surveillance of Severe Acute Respiratory Infections (SARI) in Hospitals in Spain for the 2023-24 Season]. 2023. Spanish. Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/GRIPE/Protocolos/Protocolo_Vigilancia%20centinela%20de%20IRAG_2023-24_v.27092023.pdf</eref>
  8. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-9.  https://doi.org/10.1016/S0895-4356(96)00236-3  PMID: 8970487 
  9. Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, et al. , European IVE group. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024;29(8):2400089.  https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089  PMID: 38390651 
  10. Smolarchuk C, Ickert C, Zelyas N, Kwong JC, Buchan SA. Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season. Euro Surveill. 2024;29(2):2300709.  https://doi.org/10.2807/1560-7917.ES.2024.29.2.2300709  PMID: 38214082 
  11. Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, et al. , CDC Influenza Vaccine Effectiveness Collaborators. Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States. MMWR Morb Mortal Wkly Rep. 2024;73(8):168-74.  https://doi.org/10.15585/mmwr.mm7308a3  PMID: 38421935 
  12. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: WHO; Feb 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season
  13. Skowronski DM, Zhan Y, Kaweski SE, Sabaiduc S, Khalid A, Olsha R, et al. 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN). Euro Surveill. 2024;29(7):2400076.  https://doi.org/10.2807/1560-7917.ES.2024.29.7.2400076  PMID: 38362622 
/content/10.2807/1560-7917.ES.2024.29.40.2400618
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error